Business Context and Reporting Period
Company: Accuray Incorporated (ARAY)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended December 31, 2025 (Fiscal Year 2026)
Business Overview: Accuray designs, develops, and sells advanced radiosurgery and radiation therapy systems (CyberKnife and TomoTherapy platforms) for cancer treatment. The company operates globally with significant exposure to international markets, particularly China, where it maintains a 49% joint venture (JV).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2024 |
|---|---|---|---|
| Net Revenue | $102,241 | $196,183 | $217,719 |
| Gross Profit | $24,072 | $51,083 | $76,361 |
| Gross Margin | 23.5% | 26.0% | 35.1% |
| Operating Loss | $(11,566) | $(22,879) | $2,558 |
| Net Loss | $(13,770) | $(35,448) | $(1,417) |
| Diluted EPS | $(0.11) | $(0.30) | $(0.01) |
| Cash and Cash Equivalents | $41,295 (as of Dec 31, 2025) | ||
| Total Debt (Net) | $135,887 (as of Dec 31, 2025) | ||
| Order Backlog | $383,332 (as of Dec 31, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 12% ($14.0M) for the quarter and 10% ($21.5M) for the six months compared to the prior year. This was primarily driven by a 51% drop in China revenue due to lower shipment volumes, partially offset by growth in EIMEA (+11%) and Asia Pacific (+42%).
- Margin Compression: Gross margin declined significantly from 36.1% to 23.5% (quarterly) and 35.1% to 26.0% (six months). Management attributes this to unfavorable product mix, lower unit sales, and reduced shipments from the China JV to end customers.
- Restructuring Charges: The company incurred $6.1M in restructuring charges for the quarter and $8.9M for the six months, related to a FY26 Restructuring Plan eliminating approximately 15% of the global workforce. No such charges were recorded in the prior year periods.
- Interest Expense Surge: Interest expense increased 167% to $7.7M (quarterly) due to the election of non-cash paid-in-kind (PIK) interest on the new Term Loan Facility and amortization of debt financing costs/warrants.
- Backlog Reduction: Order backlog decreased to $383.3M from $463.1M in the prior year, driven by significant age-outs ($34.4M in the quarter) and lower gross orders.
Guidance, Outlook, and Risks
- Liquidity and Debt Covenants: The company believes it has sufficient cash resources to fund operations for the next 12 months. However, it faces significant uncertainty regarding compliance with financial covenants (fixed charge coverage, leverage ratio, minimum liquidity) under its Amended Financing Agreement. Failure to comply could lead to default and acceleration of debt.
- Macroeconomic Headwinds: Management expects continued adverse impacts from inflation, supply chain challenges, and logistics costs through at least fiscal year 2026. Reduced customer budgets and longer installation timelines in the U.S. are also expected to persist.
- China and Tariffs: Sales to China remain vulnerable to U.S.-China trade tensions and tariffs. The company expects sales to China to be adversely impacted through fiscal year 2026.
- Internal Control Weaknesses: The company identified two material weaknesses in internal controls over financial reporting related to footnote disclosure reviews and the analysis of information for GAAP compliance (specifically ASC 606). Remediation efforts are underway.
- Nasdaq Listing Compliance: The company received notice from Nasdaq that its stock price closed below the $1.00 minimum bid requirement for 30 consecutive days. It has an initial 180-day compliance period to regain compliance.
- Restructuring Outlook: Total restructuring charges for the FY26 plan are expected to be approximately $13 million, substantially all to be paid in cash during fiscal year 2026.
Investor Verification Checklist
- Covenant Compliance: Verify the company's ability to meet the fixed charge coverage ratio and leverage ratio covenants under the Amended Financing Agreement, given the current operating losses and high interest expense.
- China JV Performance: Monitor the recovery of revenue from the China joint venture and the impact of ongoing tariffs and geopolitical tensions on the backlog conversion rate in that region.
- Stock Price Compliance: Track the stock price to ensure it meets the $1.00 minimum bid requirement for 10 consecutive days within the 180-day Nasdaq compliance window to avoid delisting.
- Restructuring Execution: Confirm the timeline and cost savings associated with the FY26 Restructuring Plan, specifically the elimination of 15% of the workforce and the associated $13M in total charges.
- Internal Control Remediation: Review progress on remediating the material weaknesses in internal controls to ensure future financial reporting accuracy and avoid restatements.
- Debt Maturity: Assess the plan to repay the $18.0M in 2026 Convertible Senior Notes due June 1, 2026, which are classified as short-term debt.